Full-Time

Executive Director

Clinical Science, Hematology

Posted on 10/3/2025

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$235.8k - $315.8k/yr

+ Annual Bonus + Incentive Compensation Plan + Equity Awards

Remote in USA

Remote

Category
Medical, Clinical & Veterinary (1)
Requirements
  • PharmD or PhD within clinical and/or scientific profession (or an equivalent level of professional clinical and/or scientific education, training and experience) required
  • 8 plus years of relevant experience
Responsibilities
  • Facilitate generation of, author, update, and/or review key documents, including, but not limited to: Protocol concepts, synopses, protocols, and amendments; Informed consent documents; Investigator Brochures; Clinical study reports; Abstracts, posters and manuscripts; Clinical sections of INDs (and equivalent applications), NDAs (and equivalent applications), Annual Reports, and Developmental Safety Update Reports; Clinical sections of Health Authority Briefing Documents, Orphan Drug applications, and annual reports; Risks / benefits analysis for applicable documents
  • Partner with clinical operations and other functional areas for the successful implementation and execution of clinical studies
Desired Qualifications
  • Executive presence
  • Values based collaborator - respectful, accountable and collaborative
  • Ability to relate and work with a wide range of people to achieve results
  • Effective written and verbal scientific communication
  • Successful and superior influencing skills across all levels of the organization and external collaborators
  • Problem solving and risk-mitigation skills
  • Confident, positive attitude
  • Appreciation of diversity and multiculturalism
  • Strategic and creative thinker
  • Ability to build working relations throughout the organization and with business partners to achieve business goals
  • Strong time management and organizational skills
  • Ability to manage multiple projects in a fast-paced environment
  • Skilled in multiple computer-based tools, in addition to software programs such as MS Office
  • Ethics - Treats people with respect; Inspires the trust of others; Works with integrity and ethically; Upholds organizational values
  • Planning/Organizing - Prioritizes and plans work activities; Uses time efficiently. Completes administrative tasks correctly and on time. Follows instructions and responds to management direction
  • Communication - Listens and gets clarification; Responds well to questions; Speaks clearly and persuasively in positive or negative situations. Writes clearly and informatively. Able to read and interpret written information
  • Teamwork - Balances team and individual responsibilities; Gives and welcomes feedback; Contributes to building a positive team spirit; Puts success of team above own interests; Supports everyone's efforts to succeed and contributes to building a positive team spirit; Shares expertise with others
  • Adaptability - Able to adapt to changes in the work environment. Manages competing demands. Changes approach or method to best fit the situation. Able to deal with frequent change, delays, or unexpected events
  • Technical Skills - Assesses own strengths and development areas; Pursues training and opportunities for growth; Strives to continuously build knowledge and skills; Shares expertise with others
  • Dependability - Follows instructions, responds to management direction; Takes responsibility for own actions; Keeps commitments; Commits to long hours of work when necessary to reach goals; Completes tasks on time or notifies appropriate person with an alternate plan
  • Quality - Demonstrates accuracy and thoroughness; Looks for ways to improve and promote quality; Applies feedback to improve performance; Monitors own work to ensure quality
  • Analytical - Synthesizes complex or diverse information; Collects and researches data; Uses intuition and experience to complement data
  • Problem Solving - Identifies and resolves problems in a timely manner; Gathers and analyzes information skillfully
  • Project Management - Communicates changes and progress; Completes projects on time and budget

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • TEVIMBRA Priority Review and Breakthrough Designation for HER2+ gastric cancer expands addressable market.
  • Q1 2026 revenue of $1.5B exceeds forecasts; BRUKINSA sales grew 38% year-over-year.
  • First GAAP profitability achieved in 2025 with $942M free cash flow generation.

What critics are saying

  • AbbVie's ABBV-599 Phase 3 readout H2 2026 directly challenges BRUKINSA's CLL dominance.
  • Merck's pembrolizumab FDA label expansion blocks TEVIMBRA's gastric cancer approval pathway.
  • Dr. Reddy's ibrutinib generic captures 15% CLL market share with 25% price discounts.

What makes BeOne unique

  • BRUKINSA demonstrates 74% six-year PFS and 84% OS in frontline CLL versus competitors.
  • Only BTK inhibitor showing superiority versus ibrutinib in head-to-head clinical trials.
  • Advanced ADC platform with multispecific antibodies and proprietary payload chemistry for tumor targeting.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-2%

2 year growth

5%
Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Feb 26th, 2026
BeOne Medicines reports $1.5B revenue, up 33% despite EPS miss in Q4

BeOne Medicines reported $1.5 billion in revenue for the quarter ended December 2025, a 32.8% year-over-year increase, beating the Zacks Consensus Estimate by 3.19%. The company posted earnings per share of $0.58, compared to a loss of $1.43 in the prior year, though this fell short of the $1.60 consensus estimate. Net product revenues reached $1.48 billion, exceeding the $1.45 billion analyst estimate. BRUKINSA generated $1.15 billion, surpassing the $1.09 billion estimate, whilst TEVIMBRA contributed $182 million, slightly below the $191.33 million forecast. The stock has returned 0.6% over the past month, matching the S&P 500's performance. BeOne currently holds a Zacks Rank of 2, indicating potential outperformance.

Business Wire
Feb 26th, 2026
BeOne Medicines reports $5.3B full-year revenue as BRUKINSA sales surge 49%

BeOne Medicines reported fourth quarter 2025 product revenues of $1.5 billion and full-year revenues of $5.3 billion, representing growth of 32% and 40% year-over-year respectively. Product revenue accounted for 99% of total revenue. BRUKINSA, the company's BTK inhibitor, achieved global sales of $1.1 billion in Q4 and $3.9 billion for the full year, up 38% and 49% respectively. US sales reached $845 million in Q4 and $2.8 billion annually. TEVIMBRA generated $182 million in Q4 and $737 million for the year. The company reported GAAP net income of $67 million in Q4 and $287 million for the full year, compared to losses in prior-year periods. Free cash flow reached $942 million for 2025, up $1.6 billion year-over-year. BeOne provided 2026 guidance of $6.2–6.4 billion in total revenue and $1.4–1.5 billion in non-GAAP operating income.

Yahoo Finance
Feb 2nd, 2026
BeOne Medicines trades at $340 with 51% annual return amid undervaluation signals

BeOne Medicines is trading at $340.38, representing a 9.44% year-to-date gain and 51.29% total shareholder return over the past year, though recent performance has been mixed with a one-day decline and flat weekly performance. The company appears undervalued against an estimated fair value of $401.52, based on strong revenue growth fundamentals. BeOne reported 41% year-over-year revenue growth in Q2 and raised full-year guidance to $5–5.3 billion, driven by demand for its oncology therapy BRUKINSA. The valuation narrative assumes continued aggressive expansion and rising profitability, supported by an ageing population and increased global healthcare spending. However, risks include potential competition affecting BRUKINSA revenues and possible delays in late-stage trials or regulatory approvals.

TipRanks
Nov 20th, 2025
BeOne Medicines Secures $1 Billion Financing Agreement - TipRanks.com

BeOne Medicines ( ($ONC) ) has shared an announcement. On November 13, 2025, BeOne Medicines Ltd. entered into a Facilities Agreement with HSBC and other financial ...

INACTIVE